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Abstract
Febrile cholestatic liver disease is an extremely unusual 
presentation of Hodgkin lymphoma (HL). The liver bi-
opsy of a 40-year-old man with febrile episodes and 
cholestatic laboratory pattern disclosed an uncommon 
subtype of HL, a nodular lymphocyte-predominant HL 
(NLPHL). Liver involvement in the early stage of the 
usually indolent NLPHL’s clinical course suggests an ag-
gressiveness and unfavorable outcome. Emphasizing 
a liver biopsy early in the diagnostic algorithm enables 
accurate diagnosis and appropriate treatment. Although 
rare, HL should be considered in the differential diagno-
sis of cholestasis.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Febrile cholestatic disease is a rare initial presentation of  
Hodgkin lymphoma (HL)[1]. Initial liver involvement is 
extremely rare in indolent types of  HL and more frequent 
in aggressive types of  HL such as mixed cellularity and 
lymphocytic depletion[2]. Liver involvement increases up 
to 60% postmortem in advanced stages of  the disease, as 
a result of  intra and extrahepatic infiltration by the tumor 
or due to paraneoplastic phenomenon[3]. In this report, we 
present the case of  a 40-year-old man with febrile chole-
static disease as the initial presentation of  an uncommon 
subtype of  HL - a nodular lymphocyte-predominant HL 
(NLPHL). We also discuss the challenges of  the diagnos-
tic workup and treatment, and review the literature. 
CASE REPORT
In November 2008, a 40-year-old man was referred to our 
hospital due to febrile episodes and abnormal liver tests 
that developed during the previous month. Initial liver 
function tests indicated cholestasis without hyperbilirubi-
nemia [alkaline phosphatase (AP) 1030 IU/L, γ-glutamyl 
transferase (GGT) 419 U/L and total bilirubin 14 μmol/L] 
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with an increased level of  transaminase activity [aspartate 
aminotransferase (AST) 170 IU/L and alanine aminotrans-
ferase (ALT) 156 IU/L]. A 5-d treatment of  amoxicillin-
clavulanate for Klebsiella pneumonia urinary infection, pre-
ceding the symptoms, was promptly discontinued with no 
improvement in liver tests. The initial physical examination 
was unremarkable. Abdominal ultrasound (US) revealed a 
slightly hyperechogenic liver without focal lesions and nor-
mal biliary system. Serology (hepatitis A, B, C, human im-
munodeficiency virus, Epstein-Barr virus and cytomegalovi-
rus), autoimmune studies (antinuclear, antimitochondrial, 
anti-smooth muscle and anti-liver-kidney microsomal an-
tibodies) and tumor markers (α-fetoprotein, carbohydrate 
antigen 19-9 and prostate-specific antigen) tested negative. 
There was no history of  intravenous drugs or hepatotoxic 
substances abuse. 
On admission, functional liver tests showed slight 
progression of  cholestatic pattern: AP 1511 IU/L, GGT 
516 U/L, total bilirubin 17 μmol/L, AST 200 IU/L and 
ALT 197 IU/L. Repeat physical examination revealed 
moderate hepatosplenomegaly with no peripheral lymph-
adenopathy. Abdominal US showed an enlarged, hyper-
echogenic liver without focal lesions and an enlarged 
spleen. Abdominal computed tomography (CT) scan con-
firmed the aforementioned finding with additional slightly 
enlarged retroperitoneal lymph nodes. Chest CT scan was 
normal. 
Three months after initial symptoms, liver biopsy showed 
portal areas filled with mixed inflammatory infiltrate, con-
taining lymphocytes, histiocytes, and rare atypical lymphatic 
cells with large nuclei (CD20+, CD45+). In addition to 
mild interface hepatitis, there were also signs of  mild cana-
licular and cytoplasmic cholestasis (Figure 1A). 
US of  the neck, inguinal and axillary region showed 
a single enlarged (2 cm) left axillary lymph node. Fine 
needle aspiration (FNA) of  the lymph node was sugges-
tive for HL. An extirpated axillary lymph node showed a 
pseudonodular pattern with expanded follicular dendritic 
network (highlighted with CD23 antibody), and scattered 
atypical “popcorn” cells (LP cells) that stained positively 
for CD20, CD45, PAX5 and EMA, and negatively for 
CD30, CD15, and EBV-LMP (Figure 1B) reconfirming 
the diagnosis of  nodular lymphocytic predominant HL. 
No bone marrow infiltration was found. 
The final diagnosis was advanced NLPHL (clinical 
stage ⅣB) and the initial treatment consisted of  four 
cycles of  the ABVD protocol (doxorubicin, bleomycin, 
vinblastine and dacarbazine). Evaluation after treatment 
showed no B-symptoms or signs of  peripheral adenopa-
thy, but hepatosplenomegaly and abdominal lymphade-
nopathy persisted. Disease activity was confirmed by liver 
FNA and treatment was continued with the bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, 
procarbazine and prednisone (BEACOPP) protocol. On 
the ninth day of  the new protocol the patient died due to 
sepsis. Postmortem liver specimen revealed scanty lym-
phatic portal infiltrate without LP cells. 
DISCUSSION
In this case report, the diagnosis of  HL was established by 
a liver biopsy identifying a rare subtype of  HL, NLPHL. 
The clinical and laboratory characteristics were consistent 
with febrile cholestatic disease with the exclusion of  other 
possible causes such as biliary tract obstruction, bacterial 
and viral infections, autoimmune disease or hepatotoxic 
substances. 
NLPHL is a rare subtype of  HL (representing 5% of  
HL) with unique clinicopathologic features and an indo-
lent clinical course[4]. The major pathohistological feature 
is the presence of  malignant LP cells, variants of  Reed-
Sternberg cells (CD20+CD15-CD30-) within a nodular pat-
tern of  infiltrating lymphocytes. Although initial presenta-
tion of  NLPHL is peripheral lymphadenopathy in some 
rare cases, other sites may also be involved (spleen, liver, 
lung and bone marrow)[5-10]. 
Febrile cholestatic liver disease as a first symptom is 
an extremely unusual presentation of  HL. In the only 
published series of  421 HL patients, 1.4% of  patients 
initially had cholestasis and fever with no peripheral ad-
enopathies[1]. Liver involvement of  any kind at the time of  
presentation of  HL is infrequent and ranges from 5-14%, 
but increases with advanced stages of  the disease up to 
60% postmortem[3]. 
Cholestasis in HL can be the result of  parenchymal 
infiltration by the tumor, biliary tract obstruction second-
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Figure 1  Nodular lymphocyte-predominant Hodgkin lymphoma of the liver 
and axillary lymph node. A: A portal tract showing a dense lymphoid infiltrate. 
The multiple sections revealed just a few scattered, CD20 positive neoplastic 
cells (HE stain, × 40); B: The popcorn (Hodgkin lymphoma) cells with the typi-
cally lobulated nuclei in a background of small lymphoid cells (HE stain, × 40).
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ary to extrahepatic lymphoma or paraneoplastic phenom-
enon[11]. Parenchymal involvement is the most common 
mechanism of  cholestasis and may consist of  diffuse or 
focal infiltrates, portal zone cellularity, an epithelioid cell 
reaction or as lymphoid aggregates[12]. Cholestasis second-
ary to biliary tract obstruction is rare with a frequency of  
0.5%[13]. The most rarely seen mechanism of  cholestasis 
is the paraneoplastic phenomenon in the form of  HL-
related idiopathic cholestasis (IC) and vanishing bile duct 
syndrome (VBDS). It remains controversial as to whether 
HL-related IC and VBDS represent different pathohisto-
logical entities or a spectrum of  the same disease. The ex-
act mechanism of  ductal destruction and cholestasis is un-
clear, but it is hypothesized that cytotoxic T lymphocytes 
or toxic cytokines from lymphoma cells are responsible 
for ductopenia[14]. 
In the presented case, the mechanism of  liver injury 
was parenchymal infiltration by tumor, manifested as cho-
lestasis without hyperbilirubinemia and increased transam-
inase activity. Liver involvement is a rare initial presenta-
tion of  NLPHL (2%-3%) but may lead to fulminant liver 
failure as recently described[15]. 
Moreover, liver involvement is more frequent in ag-
gressive types of  HL such as mixed cellularity and lym-
phocytic depletion[2]. The prognosis for patients with 
liver disease as the initial manifestation of  HL is generally 
poor[1,15-17], but not the rule, since some case reports show 
favorable response to chemotherapy[18-22]. Unfortunately, 
this was not the case with our patient where 3 mo after the 
appearance of  symptoms, ABVD chemotherapy resulted 
in a poor therapeutic response. After the first cycle of  the 
more aggressive BEACOPP therapy, the anti-lymphoma 
effect was sufficient, but toxicity led to a fatal outcome.
HL should be considered in the differential diagno-
sis of  cholestasis. Due to limitations in laboratory and 
morphological investigations, liver biopsy should be con-
sidered in the early phase of  the diagnostic algorithm to 
confirm the diagnosis and enable appropriate treatment.
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